Apta-3
Coagulation/Immune Disorder (unspecified)
Pre-clinicalActive
Key Facts
About Aptahem
Aptahem is a clinical-stage biotech targeting the massive unmet need in sepsis, a condition responsible for millions of deaths annually. The company's pipeline is built on a proprietary aptamer platform, with its lead asset Apta-1 designed as a multi-target emergency treatment to modulate coagulation, inflammation, and immune response. While still in early development and pre-revenue, Aptahem has secured strategic financing and is advancing its candidates toward clinical proof-of-concept in a high-value market with recent regulatory shifts potentially lowering barriers to entry.
View full company profile